BTG has expertise in developing novel NCE programmes and repositioned or reprofiled compounds. We are actively seeking to develop long-term relationships with potential partners in order to strengthen our clinical development pipeline.

We review and determine the optimum development strategy for each programme we acquire, undertaking the development alone or in collaboration, and are interested in hearing from companies with high quality programmes in the following areas:

Neurological Disorders
With three clinical stage programmes underway for the treatment of Alzheimer’s disease, multiple sclerosis and migraine, the neurology market is a primary focus for BTG. We see a high unmet need in the treatment of many neurological disorders and are looking to develop new therapeutics targeted at alleviating the disabling symptoms of these conditions.

Pain Therapeutics
BTG has several pain programmes progressing through development. We are looking to broaden our pain franchise to include opportunities in other segments of this market, including neuropathic, chronic and breakthrough pain.

Sleep Disorders
Poor sleep can contribute to depression or other mood disorders and impair the quality of life. We aim to target this market and fill the unmet need.

If you are interested in talking to BTG about opportunities in these areas, please contact us.